English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 31 October 2023, 07:00 HKT/SGT
Share:
    

Source: Molekule Consulting
Dr. Daniel Pascheles Rejoins Molekule Consulting as Strategic Advisor

MIAMI, FL, Oct 31, 2023 - (ACN Newswire) - In a significant development that promises to shape the future of Molekule Consulting, we are thrilled to announce the return of Dr. Daniel Pascheles as a Strategic Advisor.

Dr. Pascheles, with an illustrious career spanning over 30 years in the biopharmaceutical competitive and strategic intelligence sector, is poised to bring a wealth of knowledge and expertise to Molekule. His previous roles include leading Competitive Intelligence & Strategy functions at industry leaders Merck & Co./MSD and Aventis, in addition to serving as CEO of Molekule Consulting.

"Dr. Pascheles' return-to-Molekule marks a thrilling, new chapter in our shared story. His homecoming is not just a reunion, but a renewal of our mutual commitment to excellence and innovation. Welcome back, Dr. Pascheles!" expressed David Alderman, President & CEO at Molekule Consulting.

In his pivotal role as Strategic Advisor, Dr. Pascheles will employ his vast industry expertise and strategic prowess to shape and foster Molekule's trajectory of growth and value journey into the future.

"I am thrilled to be back!" remarked Dr. Pascheles. "It is with great excitement that I rejoin the dynamic and growing team at Molekule, and I eagerly anticipate contributing to the company's ongoing success."

For further details on this exciting development, please contact David Alderman at dalderman@molekuleconsulting.com; +1 305.504.3030.

About Molekule Consulting:

Molekule Consulting provides best-in-class strategic intelligence and is solely dedicated to the biopharma sector. We shape the path forward with our strategic intelligence, driving transformative changes across the biopharmaceutical landscape.

Our purpose is clear: to provide high-impact, actionable insights that catalyze growth and foster innovation for biopharmaceutical brands, franchises, and businesses. Our clientele encompasses industry titans, robust mid-sized companies, and ambitious newcomers within the global biopharmaceutical realm.

Interested in learning more about Molekule Consulting's biopharmaceutical-focused strategies and market intelligence? Dive deeper here: www.molekuleconsulting.com

Contact Information

David Alderman, President & CEO, dalderman@molekuleconsulting.com +1 305.504.3030



Topic: Press release summary
Source: Molekule Consulting

Sectors: Daily Finance
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
New Horizons for SMEs in the Johor-Singapore SEZ  
July 17, 2024 12:00 HKT/SGT
Save A Train Presents Another New and Unique Addition to its Expanding Global Rail Platform: Rail Forward!  
July 17, 2024 10:00 HKT/SGT
The Laughing Cow Brings Innovation to Snacking with Delicious Cheez Dippers  
July 17, 2024 10:00 HKT/SGT
Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship  
Tuesday, July 16, 2024 10:26:00 PM
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators  
July 16, 2024 22:00 HKT/SGT
Lexaria Preparing For Strategic Growth  
July 16, 2024 21:20 HKT/SGT
'Alamein Festival' Launches Exciting Second Edition for 2024  
July 16, 2024 21:00 HKT/SGT
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating  
July 16, 2024 20:00 HKT/SGT
How Artificial Intelligence Can Help Give Your Business a Boost  
July 16, 2024 19:30 HKT/SGT
U.S. Polo Assn. Proudly Partners with the 2024 Outsourcing Inc. Royal Charity Polo Cup  
July 16, 2024 19:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575